BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 29345160)

  • 1. Inherited forms of bladder cancer: a review of Lynch syndrome and other inherited conditions.
    Phelan A; Lopez-Beltran A; Montironi R; Zhang S; Raspollini MR; Cheng M; Kaimakliotis HZ; Koch MO; Cheng L
    Future Oncol; 2018 Feb; 14(3):277-290. PubMed ID: 29345160
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recurrent Papillary Bladder Tumors in a Boy With Lynch Syndrome.
    Tua-Caraccia R; Livingston A; Routh JC
    Urology; 2023 Nov; 181():133-135. PubMed ID: 37422136
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Liquid biopsy-based early tumor and minimal residual disease detection
    Bohaumilitzky L; Gebert J; Doeberitz MVK; Kloor M; Ahadova A
    Med Genet; 2023 Dec; 35(4):259-268. PubMed ID: 38835740
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MSH6 and PMS2 germ-line pathogenic variants implicated in Lynch syndrome are associated with breast cancer.
    Roberts ME; Jackson SA; Susswein LR; Zeinomar N; Ma X; Marshall ML; Stettner AR; Milewski B; Xu Z; Solomon BD; Terry MB; Hruska KS; Klein RT; Chung WK
    Genet Med; 2018 Oct; 20(10):1167-1174. PubMed ID: 29345684
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of Single-Nucleotide Polymorphisms and Mammographic Density Plus Classic Risk Factors for Breast Cancer Risk Prediction.
    van Veen EM; Brentnall AR; Byers H; Harkness EF; Astley SM; Sampson S; Howell A; Newman WG; Cuzick J; Evans DGR
    JAMA Oncol; 2018 Apr; 4(4):476-482. PubMed ID: 29346471
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hereditary gastrointestinal carcinomas and their precursors: An algorithm for genetic testing.
    Spoto CPE; Gullo I; Carneiro F; Montgomery EA; Brosens LAA
    Semin Diagn Pathol; 2018 May; 35(3):170-183. PubMed ID: 29397239
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutational spectrum in a worldwide study of 29,700 families with BRCA1 or BRCA2 mutations.
    Rebbeck TR; Friebel TM; Friedman E; Hamann U; Huo D; Kwong A; Olah E; Olopade OI; Solano AR; Teo SH; Thomassen M; Weitzel JN; Chan TL; Couch FJ; Goldgar DE; Kruse TA; Palmero EI; Park SK; Torres D; van Rensburg EJ; McGuffog L; Parsons MT; Leslie G; Aalfs CM; Abugattas J; Adlard J; Agata S; Aittomäki K; Andrews L; Andrulis IL; Arason A; Arnold N; Arun BK; Asseryanis E; Auerbach L; Azzollini J; Balmaña J; Barile M; Barkardottir RB; Barrowdale D; Benitez J; Berger A; Berger R; Blanco AM; Blazer KR; Blok MJ; Bonadona V; Bonanni B; Bradbury AR; Brewer C; Buecher B; Buys SS; Caldes T; Caliebe A; Caligo MA; Campbell I; Caputo SM; Chiquette J; Chung WK; Claes KBM; Collée JM; Cook J; Davidson R; de la Hoya M; De Leeneer K; de Pauw A; Delnatte C; Diez O; Ding YC; Ditsch N; Domchek SM; Dorfling CM; Velazquez C; Dworniczak B; Eason J; Easton DF; Eeles R; Ehrencrona H; Ejlertsen B; ; Engel C; Engert S; Evans DG; Faivre L; Feliubadaló L; Ferrer SF; Foretova L; Fowler J; Frost D; Galvão HCR; Ganz PA; Garber J; Gauthier-Villars M; Gehrig A; ; Gerdes AM; Gesta P; Giannini G; Giraud S; Glendon G; Godwin AK; Greene MH; Gronwald J; Gutierrez-Barrera A; Hahnen E; Hauke J; ; Henderson A; Hentschel J; Hogervorst FBL; Honisch E; Imyanitov EN; Isaacs C; Izatt L; Izquierdo A; Jakubowska A; James P; Janavicius R; Jensen UB; John EM; Vijai J; Kaczmarek K; Karlan BY; Kast K; Investigators K; Kim SW; Konstantopoulou I; Korach J; Laitman Y; Lasa A; Lasset C; Lázaro C; Lee A; Lee MH; Lester J; Lesueur F; Liljegren A; Lindor NM; Longy M; Loud JT; Lu KH; Lubinski J; Machackova E; Manoukian S; Mari V; Martínez-Bouzas C; Matrai Z; Mebirouk N; Meijers-Heijboer HEJ; Meindl A; Mensenkamp AR; Mickys U; Miller A; Montagna M; Moysich KB; Mulligan AM; Musinsky J; Neuhausen SL; Nevanlinna H; Ngeow J; Nguyen HP; Niederacher D; Nielsen HR; Nielsen FC; Nussbaum RL; Offit K; Öfverholm A; Ong KR; Osorio A; Papi L; Papp J; Pasini B; Pedersen IS; Peixoto A; Peruga N; Peterlongo P; Pohl E; Pradhan N; Prajzendanc K; Prieur F; Pujol P; Radice P; Ramus SJ; Rantala J; Rashid MU; Rhiem K; Robson M; Rodriguez GC; Rogers MT; Rudaitis V; Schmidt AY; Schmutzler RK; Senter L; Shah PD; Sharma P; Side LE; Simard J; Singer CF; Skytte AB; Slavin TP; Snape K; Sobol H; Southey M; Steele L; Steinemann D; Sukiennicki G; Sutter C; Szabo CI; Tan YY; Teixeira MR; Terry MB; Teulé A; Thomas A; Thull DL; Tischkowitz M; Tognazzo S; Toland AE; Topka S; Trainer AH; Tung N; van Asperen CJ; van der Hout AH; van der Kolk LE; van der Luijt RB; Van Heetvelde M; Varesco L; Varon-Mateeva R; Vega A; Villarreal-Garza C; von Wachenfeldt A; Walker L; Wang-Gohrke S; Wappenschmidt B; Weber BHF; Yannoukakos D; Yoon SY; Zanzottera C; Zidan J; Zorn KK; Hutten Selkirk CG; Hulick PJ; Chenevix-Trench G; Spurdle AB; Antoniou AC; Nathanson KL
    Hum Mutat; 2018 May; 39(5):593-620. PubMed ID: 29446198
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Perils of Single-Site Genetic Testing for Hereditary Cancer Syndromes in the Era of Next-Generation Sequencing.
    Casasanta N; Stark E; McHenry A; Biagi T; Kaltman R
    Oncologist; 2018 Apr; 23(4):393-396. PubMed ID: 29445031
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of Population-Based BRCA1, BRCA2, RAD51C, RAD51D, BRIP1, PALB2 Mutation Testing in Unselected General Population Women.
    Manchanda R; Patel S; Gordeev VS; Antoniou AC; Smith S; Lee A; Hopper JL; MacInnis RJ; Turnbull C; Ramus SJ; Gayther SA; Pharoah PDP; Menon U; Jacobs I; Legood R
    J Natl Cancer Inst; 2018 Jul; 110(7):714-725. PubMed ID: 29361001
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A retrospective review of 48 individuals, including 12 families, molecularly diagnosed with hereditary leiomyomatosis and renal cell cancer (HLRCC).
    Bhola PT; Gilpin C; Smith A; Graham GE
    Fam Cancer; 2018 Oct; 17(4):615-620. PubMed ID: 29423582
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Endoscopic screening for hereditary diffuse gastric cancer: one size does not fit all.
    de Almeida Artifon EL; Marinho FRT
    Gastrointest Endosc; 2018 Feb; 87(2):405-407. PubMed ID: 29406927
    [No Abstract]   [Full Text] [Related]  

  • 12. Lynch syndrome and urologic malignancies: a contemporary review.
    Lim A; Rao P; Matin SF
    Curr Opin Urol; 2019 Jul; 29(4):357-363. PubMed ID: 31045926
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lynch Syndrome: Its Impact on Urothelial Carcinoma.
    Lindner AK; Schachtner G; Tulchiner G; Thurnher M; Untergasser G; Obrist P; Pipp I; Steinkohl F; Horninger W; Culig Z; Pichler R
    Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33430305
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnosis of patients with Lynch syndrome lacking the Amsterdam II or Bethesda criteria.
    Trujillo-Rojas MA; Ayala-Madrigal ML; Gutiérrez-Angulo M; González-Mercado A; Moreno-Ortiz JM
    Hered Cancer Clin Pract; 2023 Oct; 21(1):21. PubMed ID: 37864171
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-Term Outcome of Patients with Stage II and III Muscle-Invasive Urothelial Bladder Cancer after Multimodality Approach. Which Is the Best Option?
    Trifanescu OG; Gales LN; Paun MA; Motas N; Marinescu SA; Virtosu I; Trifanescu RA; Gherghe M; Bilteanu L; Diaconu CC; Anghel RM
    Medicina (Kaunas); 2022 Dec; 59(1):. PubMed ID: 36676675
    [No Abstract]   [Full Text] [Related]  

  • 16. MutL homolog 1 germline mutation c.(453+1_454-1)_(545+1_546-1)del identified in lynch syndrome: A case report and review of literature.
    Zhang XW; Jia ZH; Zhao LP; Wu YS; Cui MH; Jia Y; Xu TM
    World J Clin Cases; 2022 Jul; 10(20):7105-7115. PubMed ID: 36051147
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune Checkpoint Inhibitors for the Treatment of Bladder Cancer.
    Lopez-Beltran A; Cimadamore A; Blanca A; Massari F; Vau N; Scarpelli M; Cheng L; Montironi R
    Cancers (Basel); 2021 Jan; 13(1):. PubMed ID: 33401585
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Yeast-based assays for the functional characterization of cancer-associated variants of human DNA repair genes.
    Cervelli T; Lodovichi S; Bellè F; Galli A
    Microb Cell; 2020 May; 7(7):162-174. PubMed ID: 32656256
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Application Areas of Traditional Molecular Genetic Methods and NGS in relation to Hereditary Urological Cancer Diagnosis.
    Mikhaylenko DS; Tanas AS; Zaletaev DV; Nemtsova MV
    J Oncol; 2020; 2020():7363102. PubMed ID: 32612654
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epidemiology of Bladder Cancer.
    Saginala K; Barsouk A; Aluru JS; Rawla P; Padala SA; Barsouk A
    Med Sci (Basel); 2020 Mar; 8(1):. PubMed ID: 32183076
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.